Loading...
Docoh

Caladrius Biosciences (CLBS)

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

Company profile

Ticker
CLBS
Exchange
CEO
David Mazzo
Employees
Incorporated
Location
Fiscal year end
Former names
CORNICHE GROUP INC /DE, NeoStem, Inc., PHASE III MEDICAL INC/DE
SEC CIK
Subsidiaries
Amorcyte, LLC • Athelos Corporation • NeoStem Oncology, LLC • As of December 31, 2019, Becton Dickinson's ownership interest in Athelos Corporation ...
IRS number
222343568

CLBS stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
18 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 33.35M 33.35M 33.35M 33.35M 33.35M 33.35M
Cash burn (monthly) (no burn) (no burn) 2.24M 2.27M 1.69M 1.7M
Cash used (since last report) n/a n/a 3.69M 3.74M 2.78M 2.79M
Cash remaining n/a n/a 29.66M 29.61M 30.57M 30.55M
Runway (months of cash) n/a n/a 13.2 13.0 18.1 18.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Jan 22 Todd C Girolamo Common Stock Payment of exercise Dispose F No No 0.8204 2,158 1.77K 160,827
14 Jan 22 David J Mazzo Common Stock Payment of exercise Dispose F No No 0.8204 6,611 5.42K 631,065
13 Jan 22 Todd C Girolamo Common Stock Payment of exercise Dispose F No No 0.8063 2,563 2.07K 162,985
13 Jan 22 David J Mazzo Common Stock Payment of exercise Dispose F No No 0.8063 6,471 5.22K 637,676
10 Jan 22 Brown Gregory B Common Stock Grant Acquire A No No 0 65,430 0 149,040
10 Jan 22 Michael H. Davidson Common Stock Grant Acquire A No No 0 65,430 0 209,753
10 Jan 22 Schwalm Cynthia Common Stock Grant Acquire A No No 0 65,430 0 145,847
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Risks
  • We currently do not meet the continued listing standards of the Nasdaq Capital Market, which require a minimum closing bid price of $1.00 per share. Our failure to meet Nasdaq’s continued listing standards could result in the delisting of our common stock, negatively impact the price of our common stock and negatively impact our ability to raise additional capital.
  • Our merger with Cend may not be consummated or may not deliver the anticipated benefits we expect.
  • Our net cash may be less than the required amount at the closing of the Merger, which would result in our stockholders owning a smaller percentage of the combined organization and could even result in the termination of the Merger Agreement.
  • Failure to complete the Merger may result in us paying a termination fee or expenses to Cend and could harm the price of our common stock and our future business and operations.
  • The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.
  • The market price of our common stock following the Merger may decline as a result of the Merger.
  • Our stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger.
  • Our stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined organization following the completion of the Merger as compared to their current ownership and voting interests.
  • During the pendency of the Merger, we may not be able to enter into a business combination with another party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect our respective businesses.
  • Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement.
  • If the conditions of the Merger are not met, the Merger will not occur.
Management Discussion
  • ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
  • We are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. We are developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Our technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.
  • Our leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories, including cardiovascular and oncology. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. Our current product candidates include:

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: ASC, case, catheter, contrast, corroborate, cumulative, formal, impairment, oncology, perspective, suspension, typically